Research Paper Volume 15, Issue 24 pp 15084—15113

Figure 6. Guidance of CMscore in the therapy for HCC patients. (A) The box and dot plot showing the value of CMscore between responders and non-responders to TACE. Wilcoxon test was used for data analyses. (B) The AUC value of CMscore in predicting non-responsiveness of HCC patients to TACE. (C) The boxplot showing the expression of ICI-related genes in high- and low-CMscore subgroups of the TCGA_LIHC dataset. (D) Correlation between CMscore and immune activity scores of each step of the Cancer-Immunity Cycle. (E) The boxplot showing the expression of cuproptosis-related genes in high- and low-CMscore subgroups of the IMvigor210 cohort. (F) The boxplot showing the level of CMscore in three immune phenotypes of mUC patients in the IMvigor210 cohort. (G) The boxplot showing the level of CMscore in mUC patients with different TC level in the IMvigor210 cohort. (H) Correlation between CMscore and CD8 T effector cell score in the IMvigor210 cohort. (I) Correlation between CMscore and level of immune checkpoint in the IMvigor210 cohort. (J) OS analyses of mUC patients with high and low CMscore in the IMvigor210 cohort. (K) Box and dot plot showing the tumor purity of metastatic melanoma patients with high and low CMscore. (L, M) OS (L) and PFS (M) analyses of metastatic melanoma patients with high and low CMscore. P-values were shown as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.